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ATYPICAL SUBACUTE SCLEROSING PANENCEPHALITIS
Case report
Marcelo Maroco Cruzeiro1, Thiago Cardoso Vale2,
Leopoldo Antônio Pires3, Gláucio Mendes Franco4
ABSTRACT - Subacute sclerosing panencephalitis (SSPE) is a progressive inflammatory disorder of the cen-
tral nervous system with both poor prognosis and high mortality. The disease has been related to a persis-
tent and aberrant measles virus infection and no effective treatment has been available. We report a case 
of SSPE with atypical features including seizures at onset and a fulminant course in a 8 years-old boy who 
had been previously immunized against measles.
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Panencefalite esclerosante subaguda: relato de caso atípico
RESUMO - Panencefalite esclerosante subaguda (PES) é uma doença inflamatória e progressiva do sistema 
nervoso central com prognóstico reservado e alta mortalidade. A doença tem sido relacionada com a infec-
ção persistente e anormal pelo vírus do sarampo e não há tratamento específico disponível. Relatamos um 
caso de PES com características atípicas representadas por início do quadro com crises convulsivas e apresen-
tação fulminante em menino de 8 anos previamente imunizado contra o vírus do sarampo.
PALAVRAS-CHAVE: panencefalite esclerosante subaguda, sarampo, imunização.
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Subacute sclerosing panencephalitis (SSPE) is a 
progressive infl ammatory disorder of the central ner-
vous system (CNS) related to a persistent and aber-
rant measles virus infection. It occurs in an incidence 
of 1 per 100,000 to 500,000 measles cases, usually af-
fecting people aged 10 to 14 years1,2. The annual inci-
dence of SSPE in both adults and children after mea-
sles infection dropped from 1 per 100,000 in the pre-
immunization era to 0.06 per 100,000 after immuni-
zation was implemented2. In developing countries, an 
incidence as high as 20-100 per 100,000 has been re-
ported2. The incidence is higher in males with a ratio 
of 2–4:1 female3. In Brazil, there are few reports avail-
able, except for the study of Nunes et al.4, in the end 
of the nineties, showing endemic regions in the coun-
try and a delay between fi rst symptoms and diagno-
sis. In India, the incidence rate is very high (21 per mil-
lion population) and linked to the high frequency of 
cases of measles among the very young5. In the classic 
form of SSPE, slow progression of neurological symp-
toms goes through four characteristic stages6,7. SSPE is 
slowly progressive with death occurring within three 
years. Up to 10% of cases show a different clinical pic-
ture with a fulminant or prolonged course5. Typical 
neurological manifestations include progressive intel-
lectual deterioration, psychomotor impairment, myo-
clonic jerks and behavioural changes, with or without 
pyramidal and extrapyramidal symptoms8.
We report the case of an 8-year-old boy present-
ing with atypical SSPE diagnosed through the clinical 
picture, electroencephalogram (EEG) and cerebrospi-
nal fl uid (CSF) analysis, after other diagnoses were ex-
cluded. The aim of this report is to emphasize the im-
portance of considering a different clinical presenta-
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tion of SSPE and its ocorrence in previously immunized 
subjects, particularly among the pediatric population.
CASE
A formely healthy 8-year-old boy presented at the neu-
rology service with a two-month history of behavioural dis-
turbances, mainly manifested by emotional lability and 
apathy associated with impairment of educational perfor-
mance. This clinical picture was followed by complex partial 
seizures with secondary generalization, with normal inter-
ictal EEG and cranial computed tomography (CT). Despite 
having been treated with gamma-aminobutyric acid, the 
patient’s condition worsened progressively in the follow-
ing two months, with amnesia, worsening of behavioural 
pattern, speech and cognitive impairment. He was hospital-
ized for further investigations. The patient did not have any 
prior history of measles infection, his immunization history 
was normal, including vaccination against measles when he 
was ten months and fi ve years old. His developmental mile-
stones were normal and there was no family background of 
neurological disorders.
Carbamazepine was prescribed due to the onset of gen-
eralized myoclonic movements and tonic seizures. Recur-
rent seizures led to the prescription of valproic acid com-
bined with clonazepam. Another EEG showed generalized 
periodic high-amplitude sharp waves. CSF analysis showed 
pleocytosis (29 leukocytes/mm3 with 69% neutrophils, 10% 
lymphocytes and 21% monocytes) and elevated protein (115 
mg/dL) and globulin levels (35 mg/dL). The measles immu-
noglobulin G titer was over 1:200 on CSF analysis and it was 
greater than the serum titer (1:80). Polymerase chain reac-
tion for Herpes simplex virus (HSV) was negative as well as 
serum and CSF Varicella zoster virus (VZV) serology.
The patient became nonverbal and developed trism and 
an irregular respiratory pattern. Physical examination re-
vealed a lethargic boy with increased muscular tone, diffuse 
rigidity, semi-opisthotonous position, mutism and decere-
bration. During his stay in hospital, a respiratory infection 
led to unsuccessful antibiotic treatment. He died after two 
months in hospital and after six months of symptom onset. 
This case report was written with the approval of the 
Ethics Committee of the University Hospital of the Federal 
University of Juiz de Fora (Minas Gerais), Brazil.
DISCUSSION
At least three of the following fi ve criteria should 
be met for SSPE diagnosis1,2: a) a typical clinical pic-
ture of progressive subacute mental deterioration 
with typical signs like myoclonus and neurodiagnos-
tic features consistent with SSPE; b) characteristic EEG 
changes; c) CSF globulin levels greater than 20% of 
total CSF protein; d) raised titers of measles antibod-
ies in blood and CSF in the absence of other antibod-
ies, including against HSV and VZV and d) typical his-
topathological fi ndings on brain biopsy or autopsy.
There are several major theories regarding the 
pathogenesis of SSPE. The chronicity of the measles vi-
rus infection, the early acquisition of measles infection 
when the immune system is immature, and the onset 
of clinical disease long after the primary infection all 
suggest an abnormal host immune response with an 
inability to clear the viral infection5,9. In addition to 
an abnormal host response, there may be immune 
modulation of the intracellular expression of the 
measles virus-encoded proteins. In early acquisition of 
measles infection, circulating maternal antibody levels 
may not be suffi cient to be protective, but may still 
modulate the virus. Anti-measles antibody produced 
in response to infection may also modulate the vi-
rus to decrease measles antigen expression. The virus 
could then evade immune recognition, and the acute 
infection would be able to convert to a chronic persis-
tent infection5. Decreased recognition by the immune 
system may also be achieved by the development of 
a mutant virus generated during acute infection.
Most patients with SSPE have a history of primary 
measles infection at an early age (<2 years), followed 
by a latent period of 6-8 years10. The risk of develop-
ing SSPE is higher when measles occurs during the 
fi rst 2 years of life, which suggests that immune im-
maturity plays an important role in the pathogen-
esis of the disease1. Widespread immunization has 
produced greater than 90% reduction in the inci-
dence of SSPE in developed nations10. Nevertheless, 
measles outbreaks still occur in countries that have 
not reached comprehensive immunization schedules 
for their whole population. Approximately, 45 million 
cases of measles, with nearly 800,000 fatalities, oc-
cur annually according to the World Health Organiza-
tion11. In underdeveloped countries, the rates of SSPE 
may be high due to higher levels of circulating wild 
type virus and infection of immunized individuals.
When the disease occurs in immunized children, as 
in our patient, it is thought to result from a subclini-
cal measles infection that occurred before 1 year of 
age, when immunization usually begins. The typical 
clinical picture of measles may have been altered by 
the presence of maternal antibodies. It has also been 
speculated that the infection in this circumstance may 
be due to infection by a wild strain which is not in-
cluded in the vaccine used12. There is no evidence to 
suggest that the attenuated vaccine virus is respon-
sible for sporadic cases of SSPE8. This issue defi nitely 
requires a wider epidemiological survey before one 
can conclude that there is a direct relationship be-
tween measles vaccination and subsequent SSPE.
In a series of 48 patients, Nunes et al.4 reported 
seven cases (14%) of SSPE in previously immunized 
patients. In the Canadian Paediatric Surveillance Pro-
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gram, Campbell et al.7 diagnosed four cases of SSPE, 
of whom one was previously immunized (25%) and 
presented with an atypical EEG pattern. Salehi et al.8 
reported three atypical cases of SSPE in immunized 
patients. In a large study conducted in India13, 307 
SSPE patients were included and nineteen (6.2%) pre-
sented with atypical features including seizures as ini-
tial manifestation. Of those patients, two developed 
SSPE despite being previously immunized. Forty-two 
cases of SSPE were diagnosed in Wales and England 
between 1990 and 2002. Four children with a history 
of receipt of a measles containing vaccine were re-
ported not to have had measles; two of these cases 
had a brain biopsy, and nucleotide sequence data con-
fi rmed wild measles infection. Brain biopsy specimens 
from a further three cases with a history of measles, 
of whom two had also had a history of vaccination, 
showed wild-type strain14. Bojinova et al.15 conducted 
a 25-year-epidemiological study in Bulgaria, where 
forty children presented with SSPE. Nine (22.5%) pre-
sented with atypical features, four (10%) with a ful-
minant course and two (5%) developed SSPE despite 
being previously immunized. In South China, Ip et al.16 
diagnosed ten cases of SSPE, of whom three (30%) 
were previously immunized. In Eastern Highlands of 
Papua Guinea, Takasu et al.17 diagnosed SSPE in 55 
patients, of whom eleven (20%) developed SSPE after 
immunization against measles.
Our patient presented behavioural disturbances, 
mainly manifested by emotional lability and apathy, 
shortly followed by seizures, regarded as an uncom-
mon initial symptom of SSPE. He had seizures in the 
fi rst Jabbour6 stage and the second one lasted only a 
couple of days, with manifestation of symptoms from 
stage III. There was only a two-month-gap period be-
tween stages I to III. Progression through these stages 
is variable with a well recognized fulminant or acute 
course where the patient develops at least 66% of 
neurological disability in the fi rst 3 months or dies 
within six months18, which was the case of our patient. 
In the series of Risk and Haddad19, approximately 10% 
of patients had such a fulminant course. In rapidly 
evolving SSPE, various stages of disease cannot be rec-
ognised. The exact mechanism producing an acute 
fulminant course is not known. Several factors such 
as exposure to measles at an early age, viral virulence, 
impaired host defense mechanisms, and concurrent 
infections with other viruses, have been suggested 
as responsible for producing a rapid course of the 
disease7,19. The disease is fatal in 90-95% of cases13.
Literature points out additional cases of SSPE with 
atypical features. These include age of onset, visual 
loss, seizures, and other focal symptoms as initial pre-
sentations, besides a lack of SSPE-specifi c EEG pattern. 
A patient could have more than one of these atypical 
features2,3,20. Our patient had seizures at the onset. 
The reasons behind the atypical presentations have 
not been elucidated. The interesting issue is that de-
spite immunization that may prime a host immune 
response to wild type measles, the virus is still able to 
persist in the CNS and cause SSPE. Does the priming 
of the immune response to measles in this setting 
predispose an individual to atypical SSPE ? This issue 
has not been systematically studied yet.
During the early phase of the illness, the EEG may 
be normal or show nonspecifi c slowing. Our patient 
presented with a characteristic EEG pattern consist-
ing of periodic generalized complexes described as 
stereotyped high-amplitude multiphasic discharges 
recurring at regular intervals of approximately 5-10 
seconds and having a 1:1 relationship with myoclonic 
jerks. Neuroimaging procedures are not necessary for 
SSPE diagnosis but may help in the differential diag-
nosis. Our patient had a normal cranial CT scan, which 
was obtained in the early stage of the disease.
Although characteristic clinical and neuroimaging 
features are helpful in making the diagnosis of SSPE, 
laboratory testing is necessary for confi rmation. In 
our patient, CSF showed pleocytosis, which is rather 
rare, as pointed out by Prashanth et al.13, who found 
it in only one of 307 Indian patients studied. In SSPE, 
specifi c measles virus antibodies are found in the CSF 
due to intrathecal production of antibodies as specifi c 
immune response to virus in the CNS. These specifi c 
antibodies help in the diagnosis as well as in the fol-
low-up of patients on treatment, as a tool to assess 
improvement13.
The pharmacologic management of SSPE can be 
divided into disease modifying agents and symp-
tomatic therapies. The latter are largely directed at 
seizure control and all the evidence is empirically 
based20. Our patient was resistant to the empirical 
treatment proposed, having had only a partial recov-
ery, which might be attributable to the natural pro-
gression of the disease as shown in stage III.
Although no treatment has proven effective, oral 
isoprinosine and intrathecal administration of α-inter-
feron may prolong survival. Many different regimens 
of antiviral and immunomodulating therapy in SSPE 
have been described, usually in small, uncontrolled 
case series. In the case of our 8-year-old patient, the 
latency of the disease was quite short and immuno-
modulating therapy was not initiated20.
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A diagnosis of SSPE was made based on three cri-
teria (clinical presentation, EEG and laboratory fi nd-
ings), combined with the exclusion of differential 
diagnoses by neuroimaging and other viral CSF se-
rologies, and the clinical course. Disease onset with 
seizures and the fulminant course determined the 
atypical presentation of our case. There was no re-
sponse to antiepileptic drugs and the patient died 
in less than 6 months after the onset of neurological 
disabilities, confi rming the fulminant presentation of 
the disease.
SSPE is often not considered because of its rarity 
and the nonspecifi c clinical manifestations at onset. It 
is a major source of morbidity and mortality in many 
regions of the developing world and therefore should 
not be forgotten. As the disorder can mimic an insidi-
ous and acute encephalopathy, it should be included 
in the differential diagnosis of encephalitis mainly in 
the youth. The pathogenesis of this disorder remains 
elusive and treating it continues to be a dauting task. 
This report should serve to disseminate among physi-
cians the possibility of SSPE arising in the context of 
normal exposures to measles virus and particularly to 
measles immunization. Awareness of the possibility 
that the clinical presentation of SSPE may be chang-
ing may increase its timely diagnosis.
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